Pharmacia & Upjohn's Fragmin reduces MI risk by 68% in patients with unstable angina -- AHA.T&G-15
PHARMACIA's FRAGMIN REDUCES RISK OF MYOCARDIAL INFARCTION BY 68% in patients with unstable coronary artery disease or non-Q-wave MI after six days of acute treatment, according to a Swedish study presented at the American Heart Association's 68th Scientific Sessions in Anaheim, Calif. Observations taken after 40 days of treatment with the low molecular weight heparin (dalteparin sodium) also indicate a reduction in death and MI, with significant reductions found in a subgroup analysis for patients with non-Q-wave MI and for non-smokers. Fragmin recently was launched in the U.S. by Pharmacia & Upjohn for deep vein thrombosis prophylaxis in abdominal surgery patients.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth